Patients with stable COPD who meet one of the following criteria: (A)with CAT score ≥10 or mMRC≥2; (B) ≥2 moderate acute exacerbation or ≥1 hospitalization in the past 12 months
Uses Budesonide MDI (Breztri Aerosphere) or Fluticasone, umeclidinium, and vilanterol (Trelegy Ellipta) or umeclidinium and vilanterol (Anoro Ellipta) as maintenance drug for COPD management
Volunteer to participate in this study and sign the informed consent form. If the subject is unable to read and sign the informed consent form due to incapacity, his/her guardian shall act on his/her behalf to read and sign the informed consent form.
You may not be if
Unstable angina or severe arrhythmia
Severe weakness-related fatigue, such as in advanced congestive heart failure or chemotherapy-related fatigue
Unstable mental illness with a risk of self-harm or harm to others
Severe cognitive impairment, progressive neuromuscular disease
Pregnant and breastfeeding women
Life expectancy of less than 6 months
Pregnant and breastfeeding women
Inability to cooperate with pulmonary function tests
Inability to complete the entire follow-up period
Vulnerable populations other than the elderly, including individuals with mental illness, cognitive impairment, critically ill patients, illiterate individuals, etc.
Clareo Health | Effectiveness of DITM Versus IMT in COPD Patients
